Huashan Hospital
Shanghai, Shanghai Municipality, 200040, China
Location status: Recruiting
Location contact
Jing Zhang, Doctor
CONTACT
Xiaojie Wu, Doctor
CONTACT
NCT Number: NCT07366866
This study is designed to evaluate the safety, tolerability, PK and PD of GenSci136 in a randomized, double-blind, placebo-controlled trial involving healthy adult participants.
Interested in participating?
Request Info18 year–45 year
All sexes
Interventional
Phase 1
Shanghai, Shanghai Municipality, 200040, China
Location status: Recruiting
Jing Zhang, Doctor
CONTACT
Xiaojie Wu, Doctor
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered SC.
Administered SC.
Time frame: Day1-Day113
Time frame: Day1-Day113
Serum concentrations at different time points will be listed and summarized by descriptive statistics.
Time frame: Day1-Day113
PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.
Time frame: Day1-Day113
PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.
Time frame: Day1-Day113
PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.
Time frame: Day1-Day113
PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.
Time frame: Day1-Day113
PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.
Time frame: Day1-Day113
PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.
Time frame: Day1-Day113
PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.
Time frame: Day1-Day113
Time frame: Day1-Day113
Contact information is provided by the study sponsor or research team.
Changchun GeneScience Pharmaceutical Co., Ltd.
Industry
A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of GenSci136 for Injection in Healthy Adult Participants in China.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00977977
Autoimmune Disease, Autoimmune Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT00943514
Abnormalities, Multiple, Autoimmune Disease
Bethesda, Maryland, United States
View Trial DetailsNCT06004349
Autoimmune Disease, Autoimmune Diseases
New York, United States
View Trial DetailsNCT03816345
Arthritis, Arthritis, Psoriatic
Birmingham, Alabama, United States
View Trial Details